异常的凝血参数与新型冠状病毒肺炎患者的预后不良有关。
Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia.
机构信息
Department of Clinical Laboratory, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
出版信息
J Thromb Haemost. 2020 Apr;18(4):844-847. doi: 10.1111/jth.14768. Epub 2020 Mar 13.
Abstract
BACKGROUND
In the recent outbreak of novel coronavirus infection in Wuhan, China, significantly abnormal coagulation parameters in severe novel coronavirus pneumonia (NCP) cases were a concern.
OBJECTIVES
To describe the coagulation feature of patients with NCP.
METHODS
Conventional coagulation results and outcomes of 183 consecutive patients with confirmed NCP in Tongji hospital were retrospectively analyzed.
RESULTS
The overall mortality was 11.5%, the non-survivors revealed significantly higher D-dimer and fibrin degradation product (FDP) levels, longer prothrombin time and activated partial thromboplastin time compared to survivors on admission (P < .05); 71.4% of non-survivors and 0.6% survivors met the criteria of disseminated intravascular coagulation during their hospital stay.
CONCLUSIONS
The present study shows that abnormal coagulation results, especially markedly elevated D-dimer and FDP are common in deaths with NCP.
摘要
背景
在中国武汉爆发的新型冠状病毒感染疫情中，重症新型冠状病毒肺炎（NCP）患者的凝血参数明显异常，引起关注。
目的
描述 NCP 患者的凝血特征。
方法
回顾性分析了同济医院 183 例确诊为 NCP 的连续患者的常规凝血结果和结局。
结果
总体死亡率为 11.5%，与幸存者相比，非幸存者入院时 D-二聚体和纤维蛋白降解产物（FDP）水平明显升高，凝血酶原时间和活化部分凝血活酶时间延长（P<.05）；非幸存者中有 71.4%和幸存者中有 0.6%符合住院期间弥散性血管内凝血的标准。
结论
本研究表明，异常的凝血结果，特别是 D-二聚体和 FDP 显著升高，在 NCP 死亡患者中很常见。
相似文献
1
Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia.异常的凝血参数与新型冠状病毒肺炎患者的预后不良有关。
J Thromb Haemost. 2020 Apr;18(4):844-847. doi: 10.1111/jth.14768. Epub 2020 Mar 13.
2
Prominent changes in blood coagulation of patients with SARS-CoV-2 infection.SARS-CoV-2 感染患者凝血功能的显著变化。
Clin Chem Lab Med. 2020 Jun 25;58(7):1116-1120. doi: 10.1515/cclm-2020-0188.
3
Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia.新型冠状病毒肺炎重型患者静脉血栓栓塞症发病情况。
J Thromb Haemost. 2020 Jun;18(6):1421-1424. doi: 10.1111/jth.14830. Epub 2020 May 6.
4
COVID-19 coagulopathy: An in-depth analysis of the coagulation system.COVID-19 凝血功能障碍：对凝血系统的深入分析。
Eur J Haematol. 2020 Dec;105(6):741-750. doi: 10.1111/ejh.13501. Epub 2020 Aug 19.
5
Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy.抗凝治疗与伴有凝血功能障碍的严重 2019 冠状病毒病患者的死亡率降低相关。
J Thromb Haemost. 2020 May;18(5):1094-1099. doi: 10.1111/jth.14817. Epub 2020 Apr 27.
6
Meta-analysis of coagulation parameters associated with disease severity and poor prognosis of COVID-19.Meta 分析与 COVID-19 疾病严重程度和预后不良相关的凝血参数。
Int J Infect Dis. 2020 Nov;100:441-448. doi: 10.1016/j.ijid.2020.09.021. Epub 2020 Sep 15.
7
Thrombo-inflammatory features predicting mortality in patients with COVID-19: The FAD-85 score.预测COVID-19患者死亡率的血栓炎症特征：FAD-85评分
J Int Med Res. 2020 Sep;48(9):300060520955037. doi: 10.1177/0300060520955037.
8
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.中国武汉成人 COVID-19 住院患者的临床病程和死亡危险因素：一项回顾性队列研究。
Lancet. 2020 Mar 28;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3. Epub 2020 Mar 11.
9
Haematological characteristics and risk factors in the classification and prognosis evaluation of COVID-19: a retrospective cohort study.新冠病毒肺炎分类及预后评估中的血液学特征与危险因素：一项回顾性队列研究
Lancet Haematol. 2020 Sep;7(9):e671-e678. doi: 10.1016/S2352-3026(20)30217-9. Epub 2020 Jul 10.
10
D-Dimer and Prothrombin Time Are the Significant Indicators of Severe COVID-19 and Poor Prognosis.D-二聚体和凝血酶原时间是严重 COVID-19 和不良预后的重要指标。
Biomed Res Int. 2020 Jun 16;2020:6159720. doi: 10.1155/2020/6159720. eCollection 2020.
引用本文的文献
1
SARS-CoV-2 Pneumonia: Advances in Diagnosis and Treatment.严重急性呼吸综合征冠状病毒2型肺炎：诊断与治疗进展
Microorganisms. 2025 Jul 31;13(8):1791. doi: 10.3390/microorganisms13081791.
2
Findings and outcomes of hospitalized unvaccinated patients during the COVID-19 pandemic: impact of comorbidities on clinical, laboratory, and immunological parameters.新冠疫情期间未接种疫苗的住院患者的研究结果与转归：合并症对临床、实验室及免疫学参数的影响
Rev Inst Med Trop Sao Paulo. 2025 Aug 25;67:e59. doi: 10.1590/S1678-9946202567059. eCollection 2025.
3
Case Report: Diagnosis, treatment and follow-up of venous thrombosis in adolescent diabetic patients with SARS-CoV-2.病例报告：感染SARS-CoV-2的青少年糖尿病患者静脉血栓形成的诊断、治疗及随访
Front Pediatr. 2025 Aug 11;13:1562590. doi: 10.3389/fped.2025.1562590. eCollection 2025.
4
Impact of gardenia extract on coagulation function in rats with acute myocardial ischemia model.栀子提取物对急性心肌缺血模型大鼠凝血功能的影响
Thromb J. 2025 Aug 25;23(1):80. doi: 10.1186/s12959-025-00768-y.
5
Blood component utilization in hospitalized COVID-19 patients: Experience from a dedicated COVID-19 center.住院COVID-19患者的血液成分使用情况：来自一家专门的COVID-19中心的经验。
Asian J Transfus Sci. 2025 Jan-Jun;19(1):108-113. doi: 10.4103/ajts.ajts_179_21. Epub 2022 Dec 12.
6
COVID-19: a vascular nightmare unfolding.新冠病毒肺炎：一场正在展现的血管噩梦。
Front Immunol. 2025 Aug 1;16:1593885. doi: 10.3389/fimmu.2025.1593885. eCollection 2025.
7
COVID-19 Organ Injury Pathology and D-Dimer Expression Patterns: A Retrospective Analysis.新型冠状病毒肺炎器官损伤病理学与D-二聚体表达模式：一项回顾性分析
Diagnostics (Basel). 2025 Jul 24;15(15):1860. doi: 10.3390/diagnostics15151860.
8
Thrombomodulin resistance as a novel prothrombotic pathway in COVID-19.血栓调节蛋白抵抗作为新冠病毒病中一种新的促血栓形成途径。
Sci Rep. 2025 Aug 12;15(1):29570. doi: 10.1038/s41598-025-15679-1.
9
Paroxysmal Nocturnal Hemoglobinuria: A Case Report in a Pandemic Environment.阵发性夜间血红蛋白尿：大流行环境下的一例病例报告
Reports (MDPI). 2023 Sep 8;6(3):42. doi: 10.3390/reports6030042.
10
Long-Term Hemostatic and Endothelial Dysregulation Associated with Cardiovascular Events in Survivors of COVID-19 Previously Admitted to the ICU.新冠病毒疾病（COVID-19）幸存者既往入住重症监护病房（ICU）后，长期止血和内皮功能失调与心血管事件相关。
Int J Mol Sci. 2025 Jul 17;26(14):6854. doi: 10.3390/ijms26146854.
本文引用的文献
1
Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China.《武汉 2019 年新型冠状病毒感染的肺炎 138 例住院患者临床特征分析》
JAMA. 2020 Mar 17;323(11):1061-1069. doi: 10.1001/jama.2020.1585.
2
Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study.中国武汉 99 例 2019 年新型冠状病毒肺炎患者的流行病学和临床特征：描述性研究。
Lancet. 2020 Feb 15;395(10223):507-513. doi: 10.1016/S0140-6736(20)30211-7. Epub 2020 Jan 30.
3
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.中国武汉地区 2019 年新型冠状病毒感染患者的临床特征。
Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. Epub 2020 Jan 24.
4
A Novel Coronavirus from Patients with Pneumonia in China, 2019.2019 年中国肺炎患者中的一种新型冠状病毒。
N Engl J Med. 2020 Feb 20;382(8):727-733. doi: 10.1056/NEJMoa2001017. Epub 2020 Jan 24.
5
Mechanisms of severe acute respiratory syndrome coronavirus-induced acute lung injury.严重急性呼吸综合征冠状病毒导致急性肺损伤的机制。
mBio. 2013 Aug 6;4(4):e00271-13. doi: 10.1128/mBio.00271-13.
6
Plasminogen controls inflammation and pathogenesis of influenza virus infections via fibrinolysis.纤溶酶原通过纤维蛋白溶解来控制流感病毒感染的炎症和发病机制。
PLoS Pathog. 2013 Mar;9(3):e1003229. doi: 10.1371/journal.ppat.1003229. Epub 2013 Mar 21.
7
Thrombocytopenia and thrombosis in disseminated intravascular coagulation (DIC).弥散性血管内凝血（DIC）中的血小板减少症和血栓形成。
Hematology Am Soc Hematol Educ Program. 2009:240-6. doi: 10.1182/asheducation-2009.1.240.
8
Use of soluble fibrin antigen instead of D-dimer as fibrin-related marker may enhance the prognostic power of the ISTH overt DIC score.使用可溶性纤维蛋白抗原而非D-二聚体作为纤维蛋白相关标志物，可能会增强国际血栓与止血学会显性弥散性血管内凝血（ISTH overt DIC）评分的预后评估能力。
Thromb Haemost. 2004 Apr;91(4):812-8. doi: 10.1160/TH03-09-0577.
9
Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation.关于弥散性血管内凝血的定义、临床及实验室标准和评分系统
Thromb Haemost. 2001 Nov;86(5):1327-30.
Zotero 插件